Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz250.017
Abstract: Abstract Background Randomised phase 3 trials have demonstrated that poly (ADP-ribose) polymerase (PARP) inhibitors significantly improve progression-free survival in BRCA-mutant high-grade serous and endometrioid ovarian carcinoma. Consequently, the demand for germline and tumour BRCA1/2testing has… read more here.
Keywords: brca1 2testing; brca1; tumour brca1; cancer ... See more keywords
Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pathology"
DOI: 10.1136/jcp-2022-208369
Abstract: Aims Clinical guidelines recommend testing both germline and tumour DNA for BRCA1/2 pathogenic variants (PVs) in non-mucinous high-grade epithelial ovarian cancer (NMEOC). In this study, we show that some tumour BRCA1/2 PVs are highly likely… read more here.
Keywords: brca1; tumour brca1; germline; brca1 pvs ... See more keywords